According to Alnylam, the research showed that binary combinations of so-called lipidoids can be “formulated together in a single lipid nanoparticle formulation to achieve synergistic gene silencing effects both in vitro and in vivo.
The algorithm, which was developed by researchers at MIT and validated by a team at Novartis, lets users identify regions on antibodies that are prone to aggregation and then predict mutations to improve the stability of biotherapeutic formulations.
Using a combination of multiplex automated genome engineering (MAGE) and conjugative assembly genome engineering (CAGE), a research team has generated bacterial strains in which one stop codon has been replaced with another.
According to the amended complaint, University of Utah's Brenda Bass had “so well-defined” the concept at issue that it "could have been reduced to practice by someone with ordinary skill in the art without further research.”
Alnylam said that as part of the agreement, it would allow Merck, the parent company of one-time rival Sirna Therapeutics, to sub-license a portion of the disputed IP to which it previously did not have access.
Using a new phylogenomic method known as the "analyzer of gene and species trees," or AnGST method, researchers from the Massachusetts Institute of Technology and the Broad Institute have gained insights into a period of gene expansion that occurred billions of years ago.